Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT01837251 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT01837251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Lead sponsor
AGO Research GmbH
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
January 31, 2021
Enrollment
682 (actual)
Sites
193

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent platinum-sensitive ovarian cancer